Riitta Lassila on LMWH Benefits in COVID19
Riitta Lassila, Professor of Coagulation Medicine at University of Helsinki, shared on LinkedIn:
”We are happy to report RDW benefits from early high risk (the same for corona disease progression and thrombosis) – targeted LMWH prophylaxis initiated at outpatient setting.
The two first virus waves when vaccination program had only started.
Lessons for any future severe viral outbursts.”
Read the full article here.
Article: Early outpatient use of low-molecular-weight heparin benefits COVID-19 outcome in association with hospitalization – Lessons learned
Authors: Miika Koskinen, Eeva Ruotsalainen, Mia Wallin, Hilkka Kivelä, Kerstin Carlsson, Jari Petäjä, Eero Hirvensalo, Markku Mäkijärvi, Riitta Lassila
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 24, 2026, 08:55Andres Gudino: Clot Characterization Through Hounsfield Units in Ischemic Stroke
-
Sep 24, 2026, 06:52Gina Sado: Screening-Detected Atrial Fibrillation Carries High Risk of Heart Failure
-
Sep 24, 2026, 06:33Benjamin Vipler: Optimal Oral Anticoagulation Choice in Atrial Fibrillation and Advanced CKD
-
Sep 24, 2026, 06:08Christopher Salerno: AI-Powered At-Home Anemia Screening Advances Telehealth Access
-
Sep 24, 2026, 05:38Aya Qattan: When a Normal CBC Does Not Mean Normal Iron Status
-
Sep 24, 2026, 05:11Mastering Warm Autoimmune Hemolytic Anemia Diagnosis and Practice – ASH Education
-
Sep 23, 2026, 16:04Monia Ezzalfani: Advancing Patient-Centered Care in Hemophilia A and B
-
Sep 23, 2026, 15:49Bilge Başak: How Activated PRP Modulates Osteoarthritic Chondrocyte Function
-
Sep 23, 2026, 14:50Mbonjo Bitsie Dora: Strengthening Sickle Cell Care Through Education, Awareness and Innovation